Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
Numinus Wellness Inc. (NUMIF) is a mental health care company dedicated to advancing traditional and innovative behavioral health treatments through safe, evidence-based psychedelic-assisted therapies. They aim to heal rather than manage symptoms of depression, anxiety, trauma, pain, and substance use. By leading the integration of psychedelic-assisted therapies into mainstream clinical practice, Numinus is pioneering a healthier society. Numinus helps individuals heal and be well by providing innovative mental health care and access to safe, evidence-based therapies.
Numinus Wellness reported a remarkable 240% year-over-year revenue growth to $0.8 million for Q2 2022, driven by acquisitions. Gross margin surged to 29.1% from 6.5% in Q1 2022. The company generated a gross profit of $228,759, marking a 349% increase from the prior quarter. Despite these gains, Numinus faced a loss of $7.8 million. The company concluded the quarter with $48.3 million in cash. A proposed acquisition of Novamind is anticipated to increase revenue significantly, positioning Numinus as a leader in psychedelic-assisted therapies.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) will participate in two virtual investor conferences in April 2022. Payton Nyquvest, Founder and CEO, is scheduled to present at the Sequire Cannabis & Psychedelic Conference on April 20 at 1:00 p.m. ET and at the KCSA Psychedelics Investor Conference on April 27 at 1:00 p.m. ET. Numinus focuses on mental health care, developing and delivering innovative therapies, including psychedelic-assisted treatments. For more details, visit www.numinus.com.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has initiated the first MDMA-assisted therapy session at its clinics in Montreal and Vancouver as part of the MAPPUSX clinical trial for PTSD. This study is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and focuses on the safety and efficacy of MDMA-assisted psychotherapy. The Montreal site recently began drug administration under the supervision of experienced therapists. This advancement signifies Numinus's commitment to integrating psychedelic therapies into clinical practice and enhancing treatment accessibility.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) will participate in Maxim Group's 2022 Virtual Growth Conference from March 28-30, 2022. A presentation by Founder and CEO Payton Nyquvest will be available on-demand starting March 28 at 9:00 a.m. ET. Interested participants can register here. Numinus focuses on innovative mental health care and evidence-based psychedelic therapies aimed at addressing conditions like depression and anxiety.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) has received approval from the Public Health Agency of Canada for a Containment Level 2 license at its Numinus Bioscience lab. This enhancement enables advanced research on natural psychedelics, focusing on studies involving Psilocybe mushrooms and their effects on the human body. The license will facilitate tests that support innovative intellectual property development and revenue generation through contract research services. The company aims to advance its psychedelic research initiatives and enhance the accessibility of psychedelic-assisted therapies.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has received approval from Health Canada to expand its research license, allowing the study of Ayahuasca and San Pedro at its Numinus Bioscience facility. This expansion positions Numinus as a key player in psychedelic research, complementing ongoing studies on Psilocybe species. The renewed license permits work with several botanical materials essential for Ayahuasca, including Banisteriopsis caapi and Psychotria viridis. Numinus aims to deepen the scientific understanding of these compounds' therapeutic applications.
On February 28, 2022, Numinus Wellness announced the results from its Annual General and Special Meeting of Shareholders, with 12.73% of common shares represented. Five directors were elected, including Payton Nyquvest and Edwin Garner, with approval rates ranging from 74.27% to 96.65%. Shareholders also approved resolutions regarding the number of directors, the appointment of auditors Davidson & Company LLP, and the Omnibus Equity Incentive Plan. For further details, the Management Information Circular is available on SEDAR.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) will participate in the AAAS 2022 Annual Meeting from February 17-20, 2022. Dr. Devon Christie will discuss frontier psychedelic research, alongside notable scientists such as Dr. Robin Carhart-Harris and Dr. Frederick Barrett. The session, titled "Psychedelic Research: Moving Beyond the Social and Political Stigma," is scheduled for February 19 at 3:00 p.m. ET. Additionally, a media availability session is set for February 20 at 9:00 a.m. ET. Numinus focuses on innovative mental health treatments, emphasizing safe, evidence-based psychedelic therapies.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announces the formation of a new Bioscience Advisory Board with the appointment of three experts: Graham Pechenik, Dr. Paul Spagnuolo, and Dr. Cory Harris. These appointments aim to enhance Numinus' intellectual property strategy and strengthen its project pipeline in psychedelic-assisted therapies. The advisors bring extensive backgrounds in patent law, nutraceuticals, and ethnobotany, reflecting Numinus' commitment to developing innovative mental health solutions and advancing its clinical trial activities.
Numinus Wellness Inc. (TSX: NUMI; OTCQX: NUMIF) has announced its move to the OTCQX® Best Market in the U.S., effective January 27, 2022. This transition from the Pink market aims to enhance visibility and accessibility for U.S. investors, as the company expands its network of Numinus Health wellness clinics. The OTCQX Market is tailored for established companies meeting specific financial and governance standards, which may boost Numinus' profile within the U.S. investment community.
FAQ
What is the current stock price of Numinus Wellness (NUMIF)?
What is the market cap of Numinus Wellness (NUMIF)?
What is Numinus Wellness Inc. focused on?
What is Numinus Wellness Inc.'s mission?
How does Numinus Wellness Inc. contribute to mental health care?
What sets Numinus Wellness Inc. apart from other mental health care providers?
What is the goal of Numinus Wellness Inc. in the mental health care space?
